Welcome to our dedicated page for INNOCAN PHARMA NEW news (Ticker: INNPD), a resource for investors and traders seeking the latest updates and insights on INNOCAN PHARMA NEW stock.
Innocan Pharma Corporation (INNPD) reports company developments in pharmaceutical biotechnology, with a focus on its LPT-CBD product candidate for animal health. LPT-CBD, or Liposome Platform Technology-Cannabidiol, is being developed as a subcutaneous injection for the management of chronic pain in dogs.
Recurring news themes include FDA Center for Veterinary Medicine fee-waiver decisions, animal drug application matters, clinical and regulatory disclosures, canine osteoarthritis study results, shareholder voting matters, capital-structure updates, and operating and financial results.
Innocan (OTCQB: INNPD) announced that the FDA Center for Veterinary Medicine granted a sponsor fee waiver for its LPT-CBD program for 2026, marking the third consecutive annual waiver. The waiver recognizes innovation for Innocan's liposomal CBD subcutaneous candidate for chronic pain in dogs.
In a randomized, blinded crossover study in osteoarthritic dogs, LPT-CBD showed a statistically significant reduction in pain versus placebo and improvements in overall well-being; company statements highlight a once-monthly subcutaneous dosing approach.
Innocan Pharma (OTCQB: INNPD) announced peer-reviewed publication of a randomized, blinded, placebo-controlled crossover trial showing a single 7 mg/kg subcutaneous injection of LPT-CBD produced statistically significant pain and function improvements in dogs with osteoarthritis versus placebo.
Key results: n=8 dogs, owner-reported function improved in 100% vs 25% (p=0.0217); reductions in lameness (p=0.033) and pain (p=0.005); measurable plasma CBD up to 4 weeks; only minor, transient adverse events. Ongoing FDA discussions noted.
Innocan Pharma (symbol: INNPD) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to listing application approval and continued compliance with exchange rules. The company said its common shares are expected to continue trading on OTCQB until the close of market on or about January 6, 2026, after which OTCQB trading will terminate upon NYSE effectiveness. Innocan will remain listed on the Canadian Securities Exchange under INNO. Concurrently, the company is conducting a securities offering subject to market conditions and regulatory approval; additional offering details will be disclosed in SEC and SEDAR+ filings.